New User:

Forgot your password?

Stock Market & Financial Investment News

News Breaks
August 12, 2014
11:20 EDTCYTXCytori Therapeutics reports publication of six month data from scleroderma study
Cytori Therapeutics (NASDAQ: CYTX) today announced that six month outcomes from a 12 patient independent investigator-initiated study using Cytori Cell Therapy to treat scleroderma have been published in the Annals of Rheumatic Disease. Data from the study indicated that treatment with Cytori Cell Therapy was safe and well tolerated through six months. In addition, the data indicated an approximately 50% average improvement across four key, validated endpoints used to assess the clinical status in patients with systemic scleroderma with impaired hand function at two months, with benefits sustained through six month follow-up. “After six month follow up, we are encouraged by the results that have been seen by the investigators in France...The investigators in Marseille have continued to follow the patients and are considering a larger, controlled study based on these positive outcomes,” said Dr. Steven Kesten, Chief Medical Officer, Cytori.
News For CYTX From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
September 24, 2014
15:34 EDTCYTXCytori Therapeutics restructuring, new alignment positive, says Maxim
Subscribe for More Information
September 22, 2014
08:12 EDTCYTXCytori sees 'modest overall revenue growth' in FY14
The company said, "Despite the impact of the cost reduction efforts, Cytori continues to anticipate modest overall revenue growth in 2014. Overall revenue growth in 2015 and 2016 will likely continue to be modest but should show a positive contribution margin beginning in 2015 based on the combination of recent expense reductions and forecasted increases in sales to Lorem Vascular and other partners, as well as through Cytori’s leaner direct sales teams in both Japan and Europe." FY14 revenue consensus $15.06M.
08:05 EDTCYTXCytori announces restructuring, cost reduction plans
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the disclaimer & terms of use